NLP · 3-line summary

AI Articles & Report Summaries

Expert articles and reports as a 3-line summary + takeaway

All Industrials Big Tech Macro Financials Consumer Energy Bio Semis Battery

BioLive Wire · AI-collected

PHC Holdings Surges to Near 4-Year High After Toho Takeover Proposal Confirmed

PHC Holdings shares surged to near a 4-year high after a Toho takeover proposal was confirmed, according to an Investing.com report.

Published Oct 1Source: Investing.com ↗

BioLive Wire · AI-collected

Lilly's Foundayo Shows Cardiovascular Safety in Diabetes Trial

Eli Lilly's Foundayo showed cardiovascular safety in a diabetes trial, according to an Investing.com report.

Published Sep 30Source: Investing.com ↗

BioLive Wire · AI-collected

Liquidia Shares Crater After Court Rules for United Therapeutics

Liquidia shares cratered after a court ruled for United Therapeutics, according to an Investing.com report.

Published Sep 30Source: Investing.com ↗

BioLive Wire · AI-collected

Connect Biopharma Stock Jumps on Positive COPD Trial Data

Connect Biopharma stock jumped on positive COPD (chronic obstructive pulmonary disease) trial data, according to an Investing.com report.

Published Sep 30Source: Investing.com ↗

BioLive Wire · AI-collected

Dyne Therapeutics Stock Rises on Positive DM1 Trial Results

Dyne Therapeutics shares rose on positive DM1 (myotonic dystrophy type 1) trial results, according to an Investing.com report.

Published Sep 29Source: Investing.com ↗

BioLive Wire · AI-collected

Pyxis Oncology Stock Falls on Public Offering Announcement

Pyxis Oncology shares fell after the company announced a public offering, according to an Investing.com report.

Published Sep 29Source: Investing.com ↗

BioLive Wire · AI-collected

Lundbeck Approaches Xeris Biopharma Over Potential Takeover, Bloomberg Reports

Lundbeck approached Xeris Biopharma over a potential takeover, according to a Bloomberg report relayed by Investing.com.

Published Sep 29Source: Investing.com ↗

BioLive Wire · AI-collected

AstraZeneca Buys Stake in Summit Therapeutics

AstraZeneca bought a stake in Summit Therapeutics, according to an Investing.com report.

Published Sep 29Source: Investing.com ↗

BioLive Wire · AI-collected

Iovance Shares Jump in Premarket as Raised Outlook Clears Consensus Views

Iovance Biotherapeutics shares jumped in premarket trading after the company raised its outlook and cleared consensus views, according to an Investing.com report.

Published Sep 29Source: Investing.com ↗

BioLive Wire · AI-collected

uniQure Plunges 65% as 48-Month Huntington's Gene Therapy Data Misses Key Stat

uniQure shares plunged 65% after its 48-month Huntington's disease gene therapy data missed a key statistic, according to an Investing.com report.

Published Sep 29Source: Investing.com ↗

BioLive Wire · AI-collected

Novo Nordisk Strikes Second Licensing Deal Since Frosty Capital-Markets Day

Novo Nordisk struck its second licensing deal since a frosty capital-markets day, according to a MarketWatch report.
This follows an earlier report of a $2.6 billion drug deal Novo Nordisk signed with Hengrui Pharma.

Published Sep 29Source: MarketWatch ↗

BioLive Wire · AI-collected

Hengrui Pharma Shares Rise as Novo Nordisk Signs $2.6 Billion Drug Deal

Hengrui Pharma shares rose after Novo Nordisk signed a $2.6 billion drug deal with the company, according to an Investing.com report.

Published Sep 29Source: Investing.com ↗

BioLive Wire · AI-collected

Summit Shares Surge After-Hours on $2 Billion AstraZeneca Equity Deal

Summit shares surged after-hours on a $2 billion equity deal with AstraZeneca, according to an Investing.com report.

Published Sep 28Source: Investing.com ↗

BioLive Wire · AI-collected

Pfizer, BioNTech and Moderna Lose Bid to Dismiss Bayer Patent Case

Pfizer, BioNTech and Moderna lost their bid to dismiss a patent case brought by Bayer, according to an Investing.com report.

Published Sep 28Source: Investing.com ↗

BioLive Wire · AI-collected

Novo Nordisk Licenses Nanexa Drug Tech in Deal Worth Up to €1.17 Billion

Novo Nordisk licensed Nanexa's drug technology in a deal worth up to €1.17 billion, according to an Investing.com report.

Published Sep 25Source: Investing.com ↗

BioLive Wire · AI-collected

Drug Developer City Therapeutics Files for US IPO as Biotech Listings Surge

Drug developer City Therapeutics filed for a US IPO as biotech listings surge, according to an Investing.com report.

Published Sep 24Source: Investing.com ↗

BioLive Wire · AI-collected

Kyverna Stock Jumps on Positive One-Year Therapy Data

Kyverna stock jumped on positive one-year therapy data, according to an Investing.com report.

Published Sep 24Source: Investing.com ↗

BioLive Wire · AI-collected

Eli Lilly Gets FDA Approval for Once-Weekly Diabetes Insulin

Eli Lilly got FDA approval for a once-weekly diabetes insulin, according to Investing.com.

Published Sep 24Source: Investing.com ↗

BioLive Wire · AI-collected

Roche's Sefaxersen Shows Positive Results in Kidney Disease Trial

Roche's sefaxersen showed positive results in a kidney disease trial, according to Investing.com.

Published Sep 23Source: Investing.com ↗

BioLive Wire · AI-collected

Novo Nordisk Open to New York Listing Upgrade, CEO Doustdar Tells FT

Novo Nordisk is open to a New York listing upgrade, CEO Doustdar told the FT, according to an Investing.com report.

Published Sep 23Source: Investing.com ↗

BioLive Wire · AI-collected

Pfizer's Bourla Among Tech, Bank CEOs Set for Trump's State Dinner for Xi

Pfizer's Bourla is among tech and bank CEOs set to attend Trump's state dinner for Xi, according to Investing.com.

Published Sep 22Source: Investing.com ↗

BioLive Wire · AI-collected

AbbVie's Rinvoq Wins EU Approval for Pediatric Arthritis

AbbVie's Rinvoq won EU approval for pediatric arthritis, according to Investing.com.

Published Sep 22Source: Investing.com ↗

BioLive Wire · AI-collected

Iambic Therapeutics Files for IPO to Fund Cancer Drugs

Iambic Therapeutics has filed for an IPO to fund cancer drugs, according to Investing.com.

Published Sep 21Source: Investing.com ↗

BioLive Wire · AI-collected

CMS Targets 15% Medicare Lab Fee Cuts, Putting DGX and LH Revenue at Risk

CMS is targeting 15% Medicare lab fee cuts, putting revenue at Quest Diagnostics (DGX) and LabCorp (LH) at risk, according to Investing.com.

Published Sep 21Source: Investing.com ↗

NLP · 3-line summary

AI Articles & Report Summaries

Expert articles and reports as a 3-line summary + takeaway

All Industrials Big Tech Macro Financials Consumer Energy Bio Semis Battery

BioLive Wire · AI-collected

PHC Holdings Surges to Near 4-Year High After Toho Takeover Proposal Confirmed

PHC Holdings shares surged to near a 4-year high after a Toho takeover proposal was confirmed, according to an Investing.com report.

Published Oct 1Source: Investing.com ↗

BioLive Wire · AI-collected

Lilly's Foundayo Shows Cardiovascular Safety in Diabetes Trial

Eli Lilly's Foundayo showed cardiovascular safety in a diabetes trial, according to an Investing.com report.

Published Sep 30Source: Investing.com ↗

BioLive Wire · AI-collected

Liquidia Shares Crater After Court Rules for United Therapeutics

Liquidia shares cratered after a court ruled for United Therapeutics, according to an Investing.com report.

Published Sep 30Source: Investing.com ↗

BioLive Wire · AI-collected

Connect Biopharma Stock Jumps on Positive COPD Trial Data

Connect Biopharma stock jumped on positive COPD (chronic obstructive pulmonary disease) trial data, according to an Investing.com report.

Published Sep 30Source: Investing.com ↗

BioLive Wire · AI-collected

Dyne Therapeutics Stock Rises on Positive DM1 Trial Results

Dyne Therapeutics shares rose on positive DM1 (myotonic dystrophy type 1) trial results, according to an Investing.com report.

Published Sep 29Source: Investing.com ↗

BioLive Wire · AI-collected

Pyxis Oncology Stock Falls on Public Offering Announcement

Pyxis Oncology shares fell after the company announced a public offering, according to an Investing.com report.

Published Sep 29Source: Investing.com ↗

BioLive Wire · AI-collected

Lundbeck Approaches Xeris Biopharma Over Potential Takeover, Bloomberg Reports

Lundbeck approached Xeris Biopharma over a potential takeover, according to a Bloomberg report relayed by Investing.com.

Published Sep 29Source: Investing.com ↗

BioLive Wire · AI-collected

AstraZeneca Buys Stake in Summit Therapeutics

AstraZeneca bought a stake in Summit Therapeutics, according to an Investing.com report.

Published Sep 29Source: Investing.com ↗

BioLive Wire · AI-collected

Iovance Shares Jump in Premarket as Raised Outlook Clears Consensus Views

Iovance Biotherapeutics shares jumped in premarket trading after the company raised its outlook and cleared consensus views, according to an Investing.com report.

Published Sep 29Source: Investing.com ↗

BioLive Wire · AI-collected

uniQure Plunges 65% as 48-Month Huntington's Gene Therapy Data Misses Key Stat

uniQure shares plunged 65% after its 48-month Huntington's disease gene therapy data missed a key statistic, according to an Investing.com report.

Published Sep 29Source: Investing.com ↗

BioLive Wire · AI-collected

Novo Nordisk Strikes Second Licensing Deal Since Frosty Capital-Markets Day

Novo Nordisk struck its second licensing deal since a frosty capital-markets day, according to a MarketWatch report.
This follows an earlier report of a $2.6 billion drug deal Novo Nordisk signed with Hengrui Pharma.

Published Sep 29Source: MarketWatch ↗

BioLive Wire · AI-collected

Hengrui Pharma Shares Rise as Novo Nordisk Signs $2.6 Billion Drug Deal

Hengrui Pharma shares rose after Novo Nordisk signed a $2.6 billion drug deal with the company, according to an Investing.com report.

Published Sep 29Source: Investing.com ↗

BioLive Wire · AI-collected

Summit Shares Surge After-Hours on $2 Billion AstraZeneca Equity Deal

Summit shares surged after-hours on a $2 billion equity deal with AstraZeneca, according to an Investing.com report.

Published Sep 28Source: Investing.com ↗

BioLive Wire · AI-collected

Pfizer, BioNTech and Moderna Lose Bid to Dismiss Bayer Patent Case

Pfizer, BioNTech and Moderna lost their bid to dismiss a patent case brought by Bayer, according to an Investing.com report.

Published Sep 28Source: Investing.com ↗

BioLive Wire · AI-collected

Novo Nordisk Licenses Nanexa Drug Tech in Deal Worth Up to €1.17 Billion

Novo Nordisk licensed Nanexa's drug technology in a deal worth up to €1.17 billion, according to an Investing.com report.

Published Sep 25Source: Investing.com ↗

BioLive Wire · AI-collected

Drug Developer City Therapeutics Files for US IPO as Biotech Listings Surge

Drug developer City Therapeutics filed for a US IPO as biotech listings surge, according to an Investing.com report.

Published Sep 24Source: Investing.com ↗

BioLive Wire · AI-collected

Kyverna Stock Jumps on Positive One-Year Therapy Data

Kyverna stock jumped on positive one-year therapy data, according to an Investing.com report.

Published Sep 24Source: Investing.com ↗

BioLive Wire · AI-collected

Eli Lilly Gets FDA Approval for Once-Weekly Diabetes Insulin

Eli Lilly got FDA approval for a once-weekly diabetes insulin, according to Investing.com.

Published Sep 24Source: Investing.com ↗

BioLive Wire · AI-collected

Roche's Sefaxersen Shows Positive Results in Kidney Disease Trial

Roche's sefaxersen showed positive results in a kidney disease trial, according to Investing.com.

Published Sep 23Source: Investing.com ↗

BioLive Wire · AI-collected

Novo Nordisk Open to New York Listing Upgrade, CEO Doustdar Tells FT

Novo Nordisk is open to a New York listing upgrade, CEO Doustdar told the FT, according to an Investing.com report.

Published Sep 23Source: Investing.com ↗

BioLive Wire · AI-collected

Pfizer's Bourla Among Tech, Bank CEOs Set for Trump's State Dinner for Xi

Pfizer's Bourla is among tech and bank CEOs set to attend Trump's state dinner for Xi, according to Investing.com.

Published Sep 22Source: Investing.com ↗

BioLive Wire · AI-collected

AbbVie's Rinvoq Wins EU Approval for Pediatric Arthritis

AbbVie's Rinvoq won EU approval for pediatric arthritis, according to Investing.com.

Published Sep 22Source: Investing.com ↗

BioLive Wire · AI-collected

Iambic Therapeutics Files for IPO to Fund Cancer Drugs

Iambic Therapeutics has filed for an IPO to fund cancer drugs, according to Investing.com.

Published Sep 21Source: Investing.com ↗

BioLive Wire · AI-collected

CMS Targets 15% Medicare Lab Fee Cuts, Putting DGX and LH Revenue at Risk

CMS is targeting 15% Medicare lab fee cuts, putting revenue at Quest Diagnostics (DGX) and LabCorp (LH) at risk, according to Investing.com.

Published Sep 21Source: Investing.com ↗